GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
GYRE THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.09+0.01 (+0.16%)
Close on Oct 19, 2026
- Market cap
- $612.88M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
95.4%
Operating margin
9.9%+283.7 pts over 5 years
Net margin
8.5%+277.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +10.2% | +4.5% | +41.0% | – | |
| Gross profit | +9.1% | +4.5% | – | – | |
| Operating income | -28.9% | +7.7% | – | – | |
| Net income | -44.8% | +31.8% | – | – | |
| EPS, diluted | -60.0% | -12.6% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -71.4% | -77.9% | 15.7% | |
| Return on assets | -31.5% | -58.2% | 5.7% | |
| Current ratio | 1.71 | 5.03 | 6.28 | |
| Inventory turnover | – | – | 0.7× | |
| Capex to revenue | – | – | 1.0% | |
| Diluted shares | 1M | 19M | 103M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Gyre Therapeutics generated $124.98M from operations and spent $62.88M on capital expenditure, dividends and share buybacks. 28% of that went back into the business.
Generated
$124.98M
Used
$62.88M
Capital expenditure$17.85M28%Dividends$45.03M72%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin8.5%
×Asset turnover0.68×
×Equity multiplier2.74×
=Return on equity, FY202515.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 8.5% | 0.68× | 2.74× | 15.7% |
| FY2024 | 16.9% | 0.87× | 5.09× | 75.4% |
| FY2023 | -75.3% | 1.13× | 7.54× | -640.4% |
| FY2022 | 4.2% | 1.46× | 1.68× | 10.3% |
| FY2021 | -1198.3% | 0.10× | 1.28× | -150.1% |
| FY2020 | -268.5% | 0.22× | 1.34× | -77.9% |
| FY2018 | -500916.7% | 0.00× | 1.09× | -39.9% |
| FY2017 | -2118.0% | 0.03× | 1.66× | -92.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$9.88M
- Cash generatingOperating cash flow above zero$1.01M
- Return on assets improvedROA up on the prior year15.4% → 7.9%
- Earnings backed by cashOperating cash flow above net income$1.01M vs $9.88M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.32 → 6.28
- No dilutionShare count did not rise102M → 103M
- Gross margin improvedGross margin up on the prior year96.33% → 95.35%
- More efficientAsset turnover rose0.91 → 0.93